KR20190135557A - 내장통 치료용 옥시코돈의 사용 - Google Patents

내장통 치료용 옥시코돈의 사용 Download PDF

Info

Publication number
KR20190135557A
KR20190135557A KR1020197035201A KR20197035201A KR20190135557A KR 20190135557 A KR20190135557 A KR 20190135557A KR 1020197035201 A KR1020197035201 A KR 1020197035201A KR 20197035201 A KR20197035201 A KR 20197035201A KR 20190135557 A KR20190135557 A KR 20190135557A
Authority
KR
South Korea
Prior art keywords
oxycodone
pain
visceral pain
morphine
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197035201A
Other languages
English (en)
Korean (ko)
Inventor
아스브요른 모어 드류즈
라르 아렌트 닐센
Original Assignee
유로-셀티큐 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20190135557(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 유로-셀티큐 에스.에이. filed Critical 유로-셀티큐 에스.에이.
Publication of KR20190135557A publication Critical patent/KR20190135557A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020197035201A 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용 Ceased KR20190135557A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18
US60/645,490 2005-01-18
PCT/EP2006/050252 WO2006077212A1 (en) 2005-01-18 2006-01-17 Use of oxycodone for treating visceral pain

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177004572A Division KR20170021905A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207031796A Division KR20200128451A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용

Publications (1)

Publication Number Publication Date
KR20190135557A true KR20190135557A (ko) 2019-12-06

Family

ID=35871217

Family Applications (10)

Application Number Title Priority Date Filing Date
KR1020197035201A Ceased KR20190135557A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020227041445A Ceased KR20220165797A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020087029312A Ceased KR20080106991A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020237042001A Ceased KR20230170811A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020177004572A Ceased KR20170021905A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020077018905A Ceased KR20070100368A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020217034339A Ceased KR20210131450A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020127011713A Ceased KR20120089710A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020207031796A Ceased KR20200128451A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020147018838A Ceased KR20140091782A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용

Family Applications After (9)

Application Number Title Priority Date Filing Date
KR1020227041445A Ceased KR20220165797A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020087029312A Ceased KR20080106991A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020237042001A Ceased KR20230170811A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020177004572A Ceased KR20170021905A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020077018905A Ceased KR20070100368A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020217034339A Ceased KR20210131450A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020127011713A Ceased KR20120089710A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020207031796A Ceased KR20200128451A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용
KR1020147018838A Ceased KR20140091782A (ko) 2005-01-18 2006-01-17 내장통 치료용 옥시코돈의 사용

Country Status (31)

Country Link
US (2) US20080200493A1 (enExample)
EP (1) EP1838318B1 (enExample)
JP (1) JP5049139B2 (enExample)
KR (10) KR20190135557A (enExample)
CN (1) CN101106996B (enExample)
AP (1) AP2249A (enExample)
AR (1) AR052880A1 (enExample)
AT (2) ATE446092T1 (enExample)
AU (1) AU2006207498B2 (enExample)
BR (1) BRPI0606247A2 (enExample)
CA (1) CA2595043C (enExample)
CY (1) CY1109660T1 (enExample)
DE (2) DE602006009899D1 (enExample)
DK (2) DK1838318T3 (enExample)
EA (1) EA013544B1 (enExample)
ES (1) ES2333901T3 (enExample)
HR (1) HRP20090679T1 (enExample)
IL (1) IL184530A (enExample)
ME (1) ME01066B (enExample)
MX (1) MX2007007207A (enExample)
MY (1) MY144471A (enExample)
NO (1) NO338968B1 (enExample)
NZ (1) NZ555852A (enExample)
PL (1) PL1838318T3 (enExample)
PT (1) PT1838318E (enExample)
RS (1) RS51069B (enExample)
SI (1) SI1838318T1 (enExample)
TW (1) TWI432196B (enExample)
UA (1) UA85471C2 (enExample)
WO (1) WO2006077212A1 (enExample)
ZA (1) ZA200705231B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3045182T1 (en) 2005-11-14 2018-08-31 Teva Pharmaceuticals International Gmbh An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
KR101304150B1 (ko) 2008-03-04 2013-09-05 라브리스 바이올로직스 인코포레이티드 만성 통증의 치료 방법
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
BR112012004464B8 (pt) * 2009-08-28 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica
CN108014334B (zh) 2011-05-20 2021-11-30 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
PT3495392T (pt) 2011-05-20 2021-09-22 H Lundbeck As Composições anti-cgrp e a sua utilização
EA033109B1 (ru) 2011-05-20 2019-08-30 Олдербайо Холдингз Ллк Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
SMT202600087T1 (it) 2016-09-23 2026-03-09 Teva Pharmaceuticals Int Gmbh Trattamento dell’emicrania refrattaria
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
CR20210373A (es) 2019-01-08 2021-08-19 H Lundbeck As Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
GEAP202515803A (en) 2019-05-02 2025-06-10 H Lundbeck As Treatment of headache using anti-cgrp antibodies
KR20210124867A (ko) 2020-04-06 2021-10-15 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
PL187926B1 (pl) * 1996-03-25 2004-11-30 Lilly Co Eli Kompozycja farmaceutyczna do leczenia bólu
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6992193B2 (en) * 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use

Also Published As

Publication number Publication date
NO338968B1 (no) 2016-11-07
KR20170021905A (ko) 2017-02-28
MX2007007207A (es) 2007-08-15
US20150190393A1 (en) 2015-07-09
IL184530A (en) 2015-01-29
KR20140091782A (ko) 2014-07-22
DE202006019887U1 (de) 2007-07-26
PL1838318T3 (pl) 2010-03-31
CN101106996B (zh) 2013-10-23
MY144471A (en) 2011-09-30
NO20074174L (no) 2007-10-17
AU2006207498B2 (en) 2009-11-19
SI1838318T1 (sl) 2010-02-26
DK200700207U1 (da) 2007-08-24
ES2333901T3 (es) 2010-03-02
TW200637554A (en) 2006-11-01
KR20230170811A (ko) 2023-12-19
IL184530A0 (en) 2007-10-31
HK1107933A1 (en) 2008-04-25
NZ555852A (en) 2010-01-29
DK1838318T3 (da) 2010-01-04
ZA200705231B (en) 2008-06-25
ATE446092T1 (de) 2009-11-15
AU2006207498A1 (en) 2006-07-27
KR20070100368A (ko) 2007-10-10
AR052880A1 (es) 2007-04-11
AP2249A (en) 2011-07-18
HRP20090679T1 (hr) 2010-01-31
CA2595043A1 (en) 2006-07-27
RS51069B (sr) 2010-10-31
AP2007004057A0 (en) 2007-08-31
BRPI0606247A2 (pt) 2009-06-09
KR20210131450A (ko) 2021-11-02
AT9895U1 (de) 2008-05-15
KR20220165797A (ko) 2022-12-15
CN101106996A (zh) 2008-01-16
JP5049139B2 (ja) 2012-10-17
US20080200493A1 (en) 2008-08-21
US9271974B2 (en) 2016-03-01
EA200701541A1 (ru) 2008-02-28
EA013544B1 (ru) 2010-06-30
PT1838318E (pt) 2009-12-15
CA2595043C (en) 2013-11-19
TWI432196B (zh) 2014-04-01
EP1838318B1 (en) 2009-10-21
WO2006077212A1 (en) 2006-07-27
ME01066B (me) 2012-10-20
JP2008526927A (ja) 2008-07-24
CY1109660T1 (el) 2014-08-13
UA85471C2 (ru) 2009-01-26
DK200700207U3 (da) 2007-09-28
KR20200128451A (ko) 2020-11-12
KR20120089710A (ko) 2012-08-13
KR20080106991A (ko) 2008-12-09
EP1838318A1 (en) 2007-10-03
DE602006009899D1 (de) 2009-12-03

Similar Documents

Publication Publication Date Title
US9271974B2 (en) Use of oxycodone for treating visceral pain
KR20070107805A (ko) 옥시코돈 및 날록손 함유 제형
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
WO2012089738A1 (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
EA030310B1 (ru) Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
KR20250145673A (ko) 통증 완화에 유용한 요법 및 조성물
HK1107933B (en) Use of oxycodone for treating visceral pain
WO2020084348A1 (en) Oral aminodihydrophthalazinedione compositions and their use the treatment of non-viral hepatitis
AU2017276288A1 (en) Reducing drug liking in a subject

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20191128

Application number text: 1020177004572

Filing date: 20170217

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191227

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200107

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200804

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200107

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20201103

Application number text: 1020177004572

Filing date: 20170217

PJ0201 Trial against decision of rejection

Patent event date: 20201103

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20200804

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20201104

Appeal identifier: 2020101002670

Request date: 20201103

J121 Written withdrawal of request for trial
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20201104

PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20201104

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2020101002670

Request date: 20201103

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20201104

WITB Written withdrawal of application